Business UpdateMay 21, 2026, 07:32 AM
Acrivon CEO to Present at TD Cowen Oncology Innovation Summit
AI Summary
Acrivon Therapeutics announced that its President and CEO, Peter Blume-Jensen, will participate in a virtual fireside chat at TD Cowen’s 7th Annual Oncology Innovation Summit on May 26, 2026. The clinical-stage oncology company utilizes its proprietary Generative Phosphoproteomics AP3 platform for drug design and clinical development. Acrivon is advancing ACR-368 in a registrational Phase 2b study for endometrial cancer and ACR-2316 in a Phase 1/2 study, alongside preclinical programs.
Key Highlights
- Acrivon CEO Peter Blume-Jensen to participate in a virtual fireside chat at TD Cowen's 7th Annual Oncology Innovation Summit.
- The event is scheduled for Tuesday, May 26, 2026, at 9:00 a.m. ET.
- A live and archived webcast will be accessible via the company's investor relations website.
- Acrivon is advancing ACR-368 (CHK1/2 inhibitor) in a registrational Phase 2b study for endometrial cancer.
- ACR-368 has received FDA Fast Track and Breakthrough Device designations.
- The company is also progressing ACR-2316 (WEE1/PKMYT1 inhibitor) in a Phase 1/2 study.
- Multiple preclinical candidates targeting CDK11 are showing complete tumor regression in AML models.
Price Impact
More from ACRV